Gilead Sciences ((GILD)), Arcus Biosciences ((RCUS)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The recent clinical study update from Arcus Biosciences and Gilead Sciences focuses on evaluating the efficacy and safety of etrumadenant-based treatment combinations in patients with metastatic colorectal cancer. Officially titled ‘A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer,’ the study aims to explore new therapeutic options for this challenging condition.
The interventions being tested include etrumadenant, a dual adenosine receptor antagonist, in combination with zimberelimab, an anti-PD-1 monoclonal antibody, and other agents like AB680, bevacizumab, and the mFOLFOX-6 regimen. These combinations are designed to enhance antitumor activity and improve patient outcomes.
This interventional study is randomized with a parallel assignment model and single masking for the outcomes assessor. The primary purpose is treatment, focusing on the safety and efficacy of the drug combinations in treating metastatic colorectal cancer.
The study began on May 10, 2021, with an active status but not recruiting. The last update was submitted on July 30, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results.
The market implications of this study are significant for Gilead Sciences and Arcus Biosciences. Positive outcomes could boost their stock performance and investor confidence, especially in the competitive oncology sector. As the study is ongoing, investors should watch for further updates.
The study is ongoing, with further details available on the ClinicalTrials portal.